The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_004004.6(GJB2):c.563A>G (p.Lys188Arg)

CA387460893

429984 (ClinVar)

Gene: GJB2
Condition: nonsyndromic genetic deafness
Inheritance Mode: Autosomal recessive inheritance
UUID: 4695ee4b-08a2-4fd3-8d4a-f5d1dad3695c

HGVS expressions

NM_004004.6:c.563A>G
NM_004004.6(GJB2):c.563A>G (p.Lys188Arg)
NC_000013.11:g.20189019T>C
CM000675.2:g.20189019T>C
NC_000013.10:g.20763158T>C
CM000675.1:g.20763158T>C
NC_000013.9:g.19661158T>C
NG_008358.1:g.8957A>G
ENST00000382844.2:c.563A>G
ENST00000382848.5:c.563A>G
ENST00000382844.1:c.563A>G
ENST00000382848.4:c.563A>G
NM_004004.5:c.563A>G

Likely Pathogenic

Met criteria codes 3
PM2_Supporting PM3_Strong PP3
Not Met criteria codes 1
PS3

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Hearing Loss Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for CDH23, COCH, GJB2, KCNQ4, MYO6, MYO7A, SLC26A4, TECTA and USH2A Version 2

PDF
Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Hearing Loss VCEP
The NM_004004.6(GJB2):c.563A>G variant in GJB2 is a missense variant predicted to cause substitution of lysine by arginine at amino acid 188 (p.Lys188Arg). The highest population minor allele frequency of the variant is 0.00025% (3/1180000) in the European (non-Finnish) population in gnomAD v.4.0.0 (PM2_Supporting). This variant has been reported in at least three probands with hearing loss (2.5 PM3_Strong points). Two probands were compound heterozygous (one confirmed trans, the other one assumed trans) with the pathogenic c.35delG, p.G12Vfs variant (Clinvar ID: 17004, PMID 17666888, internal data from GeneDx). Another proband was compound heterozygous for the pathogenic variant p.Leu90Pro (ClinVar ID: 17016, University of Minnesota internal data). The REVEL computational prediction analysis tool produced a score of 0.9 meeting PP3. In summary, this variant meets criteria to be classified as likely pathogenic for autosomal recessive hearing loss based on the ACMG/AMP criteria applied as specified by the Hearing Loss Expert Panel: PM2_Supporting, PM3_Strong, PP3 (VCEP specifications version 2; 01.17.2024).
Met criteria codes
PM2_Supporting
The highest population minor allele frequency of the variant is 0.00025% (3/1180000) in the European (non-Finnish) population in gnomAD v.4.0.0 (PM2_Supporting).
PM3_Strong
2.5 points from 3 probands 1 proband reported in PMID 17666888 1 proband internal data from University of Minnesota internal data, p.Lys188Arg / p.Leu90Pro, trans phasing inferred from NGS data 1 proband internal data from GeneDx, p.Lys188Arg / c.35delG confirmed in trans
PP3
Revel score 0.969
Not Met criteria codes
PS3
HeLa cells transfected with Cx26 mutant vectors Fluorescence microscopy indicated that cells expressing Lys188Arg showed intracellular fluorescence (similar to S199F, path variant) Patterns indicate ER retention or cytoplasmic aggregation Indicative of mis-trafficking *Not one of our specified functional assays
Approved on: 2024-03-28
Published on: 2024-03-28
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.